Journal
JOURNAL OF DRUG TARGETING
Volume 29, Issue 2, Pages 168-184Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/1061186X.2020.1818760
Keywords
Polo-like Kinase 1; kinase inhibitors; drug targeting; anticancer therapy; drug discovery; cell signalling; apoptosis
Categories
Funding
- Council of Scientific and Industrial Research [27(0368)/20/EMRII]
Ask authors/readers for more resources
PLK1, a conserved mitotic serine-threonine protein kinase, plays important roles in cell division and genome stability. Its expression is controlled by cell cycle stages and blocking PLK1 expression can inhibit tumor cell proliferation and induce apoptosis, making it an attractive target for drug development.
Polo-like kinase 1 (PLK1) is a conserved mitotic serine-threonine protein kinase, functions as a regulatory protein, and is involved in the progression of the mitotic cycle. It plays important roles in the regulation of cell division, maintenance of genome stability, in spindle assembly, mitosis, and DNA-damage response. PLK1 is consist of a N-terminal serine-threonine kinase domain, and a C-terminal Polo-box domain (regulatory site). The expression of PLK1 is controlled by transcription repressor in the G1 stage and transcription activators in the G2 stage of the cell cycle. Overexpression of PLK1 results in undermining of checkpoints causes excessive cellular division resulting in abnormal cell growth, leading to the development of cancer. Blocking the expression of PLK1 by an antibody, RNA interference, or kinase inhibitors, causes a subsequent reduction in the proliferation of tumour cells and induction of apoptosis in tumour cells without affecting the healthy cells, suggesting an attractive target for drug development. In this review, we discuss detailed information on expression, gene and protein structures, role in different diseases, and progress in the design and development of PLK1 inhibitors. We have performed an in-depth analysis of the PLK1 inhibitors and their therapeutic implications with special focus to the cancer therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available